gatifloxacin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1280 112811-59-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gatifloxacin anhydrous
  • gatifloxin
  • gatifloxacin
  • gatifloxacin hydrate
A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
  • Molecular weight: 375.40
  • Formula: C19H22FN3O4
  • CLOGP: -0.27
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 82.11
  • ALOGS: -2.77
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 28, 2003 FDA ALLERGAN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 229.88 53.57 44 156 8363 2349522
Anaphylactic reaction 151.34 53.57 32 168 9673 2348212
Drug intolerance 124.07 53.57 29 171 13688 2344197
Hyperglycaemia 86.44 53.57 18 182 4867 2353018

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 462.57 67.91 97 325 8341 1738018
Hyperglycaemia 272.19 67.91 58 364 5107 1741252
Clostridium colitis 109.07 67.91 17 405 239 1746120
Blood glucose decreased 82.22 67.91 19 403 2306 1744053
Blood glucose increased 73.53 67.91 24 398 10560 1735799

Pharmacologic Action:

SourceCodeDescription
ATC J01MA16 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
ATC S01AE06 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Fluoroquinolones
FDA EPC N0000175937 Quinolone Antimicrobial
FDA CS M0023650 Quinolones
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
CHEBI has role CHEBI:35441 antiinfective agent
MeSH PA D059005 Topoisomerase II Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Bacterial conjunctivitis indication 128350005 DOID:9700
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Urinary tract infection caused by Klebsiella indication 369001000119100
Moraxella Catarrhalis Chronic Bronchitis indication
E. Coli Pyelonephritis indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Legionella Pneumophila Pneumonia indication
Moraxella Catarrhalis Pneumonia indication
Staphylococcus Chronic Bronchitis indication
Complicated Proteus UTI indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Skin and Skin Structure Streptococcus Infection indication
Haemophilus Influenzae Chronic Bronchitis indication
Haemophilus Parainfluenzae Pneumonia indication
Acute tuberculosis off-label use 25629007
Pulmonary tuberculosis off-label use 154283005 DOID:2957

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.23 acidic
pKa2 8.39 Basic
pKa3 1.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA gyrase Enzyme INHIBITOR CHEMBL CHEMBL
DNA topoisomerase 4 Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase subunit A Enzyme IC50 5.03 CHEMBL
DNA gyrase Enzyme IC50 6.30 CHEMBL
DNA topoisomerase 4 subunit A Enzyme IC50 5.92 CHEMBL

External reference:

IDSource
D000077734 MESH_DESCRIPTOR_UI
4021187 VUID
N0000148634 NUI
C0753645 UMLSCUI
D00589 KEGG_DRUG
371238005 SNOMEDCT_US
d04504 MMSL
8587 MMSL
228476 RXNORM
4021187 VANDF
116349004 SNOMEDCT_US
007995 NDDF
81485Y3A9A UNII
7423 INN_ID
CHEMBL31 ChEMBL_ID
DB01044 DRUGBANK_ID
180200-66-2 SECONDARY_CAS_RN
GFN PDB_CHEM_ID
CHEBI:5280 CHEBI
5379 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 0023-3615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 15 sections
ZYMAR HUMAN PRESCRIPTION DRUG LABEL 1 0023-9218 SOLUTION/ DROPS 3 mg OPHTHALMIC EXPORT ONLY 1 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 0378-5431 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 16 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-189 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 15 sections
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 54868-6303 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 16 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 57297-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 16 sections
gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 60758-615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA AUTHORIZED GENERIC 15 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 61314-672 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 14 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 68180-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 16 sections